InnovAge EPS INNV
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.02
- Latest quarter, Q4 FY26
- $0.06
- Fiscal year 2026
- −$0.02
InnovAge's earnings per share was −$0.02 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was $0.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$0.02 | n/a |
| FY2025 | −$0.23 | n/a |
| FY2024 | −$0.16 | n/a |
| FY2023 | −$0.30 | n/a |
| FY2022 | −$0.04 | n/a |
| FY2021 | −$0.37 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $0.06 | n/a | −$0.02 | |
| Q3 FY26 | −$0.22 | n/a | −$0.09 | |
| Q2 FY26 | $0.08 | n/a | $0.05 | |
| Q1 FY26 | $0.06 | n/a | −$0.13 | |
| Q4 FY25 | −$0.01 | n/a | −$0.23 | |
| Q3 FY25 | −$0.08 | n/a | −$0.23 | |
| Q2 FY25 | −$0.10 | n/a | −$0.19 | |
| Q1 FY25 | −$0.04 | n/a | −$0.12 | |
| Q4 FY24 | −$0.01 | n/a | −$0.16 | |
| Q3 FY24 | −$0.04 | n/a | −$0.23 | |
| Q2 FY24 | −$0.03 | n/a | −$0.24 | |
| Q1 FY24 | −$0.08 | n/a | −$0.28 |
Against its peers
Companies in Medical - Care Facilities nearest InnovAge's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INNVInnovAge | −$0.02 | |
| USPHU S Physical Therapy | $0.88 | −63% a year |
| PNTGPennant | $0.90 | +15% a year |
| OMDAOmada Health | $0.06 | |
| ARDTArdent Health | $0.55 | −70% a year |
| HCSGHealthcare Services | $1.72 | +176% a year |
| PGNYProgyny | $0.92 | +56% a year |
| ADUSAddus HomeCare | $5.70 | +26% a year |
| MDPediatrix Medical | $2.09 | +62% a year |
| PRVAPrivia Health | $0.21 | +91% a year |
| AVAHAveanna Healthcare | $1.23 | +1267% a year |
| Peer median | $0.91 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on InnovAge
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.